JJMM and other interested CYPH investors:
As I said before, I am not short on any stock or associated with any short players. As far as CYPH is concerned, I like the work licensed-in on the taxol biosynthetic pathway (from Rodney Croteau's lab.) This is very good and is related to the public article found in Proc. Natl. Acad. Sci. USA Vol. 95, Issue 8, 4126-4133, April 14, 1998:
This contribution is part of the special series of Inaugural Articles by members of the National Academy of Sciences elected on April 29, 1997.
Biochemistry
Plant terpenoid synthases: Molecular biology and phylogenetic analysis
(terpene cyclase / isoprenoids / plant defense / genetic engineering / secondary metabolism)
Jörg Bohlmann*,, Gilbert Meyer-Gauen, and Rodney Croteau*,§
* Institute of Biological Chemistry, Washington State University, Pullman, WA 99164-6340; and Human Genetics Center, University of Texas, Houston, TX 77225
Contributed by Rodney Croteau, February 25, 1998
This review focuses on the monoterpene, sesquiterpene, and diterpene synthases of plant origin that use the corresponding C10, C15, and C20 prenyl diphosphates as substrates to generate the enormous diversity of carbon skeletons characteristic of the terpenoid family of natural products. A description of the enzymology and mechanism of terpenoid cyclization is followed by a discussion of molecular cloning and heterologous expression of terpenoid synthases. Sequence relatedness and phylogenetic reconstruction, based on 33 members of the Tps gene family, are delineated, and comparison of important structural features of these enzymes is provided. The review concludes with an overview of the organization and regulation of terpenoid metabolism, and of the biotechnological applications of terpenoid synthase genes.
The links is:
pnas.org (This link also gives other links).
Also check out nal.usda.gov (CRMET, I think this is what you were referring to, however counterparts of all these plant genes in the taxol biosynthethic pathway have now as yet been found in fungi).
I know what I am talking about and have approached the study of Cytoclonal intellectual property from both a scientific and business analysis. JJMM, if you are interested in investing, talk to scientists, talk to business people, look at the intellectual portfolio of the company, look at management, look at the technical profile of the stock, talk to CRMET and HPARCH on Yahoo. I don't own the stock. I am not short. I am not long. I have not decided to invest in it yet. Personally I like IDPH and PMCO (very much), and ENMD, and I will even go outside my sector and recommend PSQL.
Regards,
Blackmerlin
------------------------------------------------------------------
|
